Oncolytic vaccinia virus in combination with radiation shows synergistic antitumor efficacy in pancreatic cancer

Cancer Letters

Volumn 344, Issue 2, 2014, Pages 282-290

  Dai, M H ^a   Liu, S L ^a   Chen, N G ^b,c   Zhang, T P ^a   You, L ^a   Q Zhang, F ^a   Chou, T C ^d   Szalay, A A ^b,c,e   Fong, Y ^d   Zhao, Y P ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b GENELUX CORPORATION   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Pancreatic cancer; Synergism; Virus

Indexed keywords

GLV 1H 151; ONCOLYTIC VACCINIA VIRUS; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; MONOTHERAPY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR XENOGRAFT; VACCINIA VIRUS; VIRUS REPLICATION;

GIARDIA LAMBLIA VIRUS; MUS; VACCINIA VIRUS;

PANCREATIC CANCER; SYNERGISM; VIRUS;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; HUMANS; MICE; MICE, INBRED BALB C; ONCOLYTIC VIROTHERAPY; PANCREATIC NEOPLASMS; RANDOM ALLOCATION; VACCINIA VIRUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84893698430     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.11.007     Document Type: Article

References (28)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J. Cancer statistics, 2007. CA Cancer J. Clin. 2007, 57:43-66.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63:11-30.
3. Haddad D., Chen N., Zhang Q., Chen C.H., Yu Y.A., Gonzalez L., Aguilar J., Li P., Wong J., Szalay A.A., Fong Y. A novel genetically modified oncolytic vaccinia virus in experimental models is effective against a wide range of human cancers. Ann. Surg. Oncol. 2012, 19. S665-74.
4. Dai M.H., Zamarin D., Gao S.P., Chou T.C., Gonzalez L., Lin S.F., Fong Y. Synergistic action of oncolytic herpes simplex virus and radiotherapy in pancreatic cancer cell lines. Br. J. Surg. 2010, 97:1385-1394.
5. Zhang Q., Yu Y.A., Wang E., Chen N., Danner R.L., Munson P.J., Marincola F.M., Szalay A.A. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res. 2007, 67:10038-10046.
6. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
7. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 2006, 58:621-681.
8. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Erratum in: Pharmacol. Rev. 2007, 59:124.
9. Park J.K., Kogure T., Nuovo G.J., Jiang J., He L., Kim J.H., Phelps M.A., Papenfuss T.L., Croce C.M., Patel T., Schmittgen T.D. MiR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res. 2011, 71:7608-7616.
10. Adusumilli P.S., Stiles B.M., Chan M.K., Chou T.C., Wong R.J., Rusch V.W., Fong Y. Radiation therapy potentiates effective oncolytic viral therapy in the treatment of lung cancer. Ann. Thorac. Surg. 2005, 80:409-416. discussion 416-7.
11. Advani S.J., Buckel L., Chen N.G., Scanderbeg D.J., Geissinger U., Zhang Q., Yu Y.A., Aguilar R.J., Mundt A.J., Szalay A.A. Preferential replication of systemically delivered oncolytic vaccinia virus in focally irradiated glioma xenografts. Clin. Cancer Res. 2012, 18:2579-2590.
12. Kyula J.N., Khan A.A., Mansfield D., Karapanagiotou E.M., McLaughlin M., Roulstone V., Zaidi S., Pencavel T., Touchefeu Y., Seth R., Chen N.G., Yu Y.A., Zhang Q., Melcher A.A., Vile R.G., Pandha H.S., Ajaz M., Szalay A.A., Harrington K.J. Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in (V600D/E)BRAF mutant melanoma depends on JNK and TNF-α signaling. Oncogene 2013, [Epub ahead of print].
13. Zhang M., Li S., Li J., Ensminger W.D., Lawrence T.S. Ionizing radiation increases adenovirus uptake and improves transgene expression in intrahepatic colon cancer xenografts. Mol. Ther. 2003, 8:21-28.
14. Qian J., Yang J., Dragovic A.F., Abu-Isa E., Lawrence T.S., Zhang M. Ionizing radiation-induced adenovirus infection is mediated by Dynamin 2. Cancer Res. 2005, 65:5493-5497.
15. Twigger K., Vidal L., White C.L., De Bono J.S., Bhide S., Coffey M., Thompson B., Vile R.G., Heinemann L., Pandha H.S., Errington F., Melcher A.A., Harrington K.J. Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin. Cancer Res. 2008, 14:912-923.
16. Eisenberg D.P., Adusumilli P.S., Hendershott K.J., Yu Z., Mullerad M., Chan M.K., Chou T.C., Fong Y. 5-Fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer. J. Gastrointest Surg. 2005, 9:1068-1077. discussion 1077-9.
17. Liu C., Sarkaria J.N., Petell C.A., Paraskevakou G., Zollman P.J., Schroeder M., Carlson B., Decker P.A., Wu W., James C.D., Russell S.J., Galanis E. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. Clin. Cancer Res. 2007, 13:7155-7165.
18. Liu C., Zhang Y., Liu M.M., Zhou H., Chowdhury W., Lupold S.E., Deweese T.L., Rodriguez R. Evaluation of continuous low dose rate versus acute single high dose rate radiation combined with oncolytic viral therapy for prostate cancer. Int. J. Radiat. Biol. 2010, 86:220-229.
19. DeCaprio J.A., Ludlow J.W., Figge J., Shew J.Y., Huang C.M., Lee W.H., Marsilio E., Paucha E., Livingston D.M. SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 1988, 54:275-283.
20. Goh W.C., Rogel M.E., Kinsey C.M., Michael S.F., Fultz P.N., Nowak M.A., Hahn B.H., Emerman M. HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nat. Med. 1998, 4:65-71.
21. Perwitasari O., Torrecilhas A.C., Yan X., Johnson S., White C., Tompkins S.M., Tripp R.A. Targeting cell division cycle 25 homolog B (CDC25B) to regulate influenza virus replication. J. Virol. 2013, October 9. [Epub ahead of print].
22. Wu X., Roth J.A., Zhao H., Luo S., Zheng Y.L., Chiang S., Spitz M.R. Cell cycle checkpoints, DNA damage/repair, and lung cancer risk. Cancer Res. 2005, 65:349-357.
23. Bucher N., Britten C.D. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br. J. Cancer 2008, 98:523-528.
24. Kimura M., Yoshioka T., Saio M., Banno Y., Nagaoka H., Okano Y. Mitotic catastrophe and cell death induced by depletion of centrosomal proteins. Cell. Death. Dis. 2013, 4:e603.
25. Wei D., Li H., Yu J., Sebolt J.T., Zhao L., Lawrence T.S., Smith P.G., Morgan M.A., Sun Y. Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor. Cancer Res. 2012, 72:282-293.
26. Li J., Wang Y., Sun Y., Lawrence T.S. Wild-type TP53 inhibits G(2)-phase checkpoint abrogation and radiosensitization induced by PD0166285, a WEE1 kinase inhibitor. Radiat. Res. 2002, 157:322-330.
27. Wang Y., Li J., Booher R.N., Kraker A., Lawrence T., Leopold W.R., Sun Y. Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res. 2001, 61:8211-8217.
28. Liu S., Dai M., You L., Zhao Y. Advance in herpes simplex viruses for cancer therapy. Sci. China Life Sci. 2013, 56:298-305.